Table 3.
Population pharmacokinetic parameters of CsA and bootstrap results (n = 500)
| Parameter | Final model Estimate (RSE%) | Final model CI (95%) | Bootstrap Median | Bootstrap CI (95%) |
|---|---|---|---|---|
| CL (L/h) | 42.3 (10.6) | 33.48, 51.12 | 42.16 | 32.56, 51.94 |
| V (L) | 3100 (13.1) | 2306.2, 3893.8 | 3018.87 | 2340.67, 4008.99 |
| θTAF-CL | 0.36(16.3) | 0.245, 0.475 | 0.35 | 0.226, 0.459 |
| θPOD-CL | 0.00703 (21.5) | 0.004, 0.01 | 0.0072 | 0.0044, 0.0107 |
| θPOD-V | 0.0197 (29.8) | 0.008, 0.031 | 0.0199 | 0.0084, 0.0351 |
| θeGFR-CL | 0.545 (29.9) | 0.226, 0.864 | 0.542 | 0.204, 0.932 |
| Gene-1 ON CL | 0.984 (8.1) | 0.827, 1.141 | 0.991 | 0.823, 1.189 |
| Gene-2 ON CL | 1.22 (10.1) | 0.979, 1.461 | 1.223 | 0.947, 1.536 |
| Gene-3 ON CL | 1.22 (8.9) | 1.008, 1.432 | 1.221 | 0.986, 1.458 |
| Inter-individual variability | ||||
| ω2 CL | 0.0744 (19.5) | Shrinkage-8.4% | 0.0705 | 0.044, 0.101 |
| ω2 V | 0.454 (24) | Shrinkage-27.2% | 0.447 | 0.249, 0.660 |
| Residual variability | ||||
| σ21 (%) | 0.154 (22.9) | 0.085, 0.223 | 0.152 | 0.081, 0.231 |
| σ22 (ng/mL) | 30.3 (21.7) | 17.442, 43.158 | 29.8 | 16.81, 42.86 |
CL clearance, V distribution volume, Gene = CYP3A4*G (1 for CYP3A4*G CC, 2 for CYP3A4*G TT, 3 for CYP3A4*G CT), TAF triazole antifungals, RSE% relative standard error, CI confidence interval